27 results about "Tumor proteins" patented technology

The invention relates to the technical field of medical image processing and analysis, and discloses an oncoprotein quantitative evaluation method and system based on image recognition, and the method comprises the steps: obtaining a panoramic digital image of an IHC slice, extracting a region of interest in the panoramic digital image, segmenting the region of interest to obtain high-resolution image blocks, and carrying out the segmentation of the high-resolution image blocks; inputting the high-resolution image blocks into a pre-trained FCN model, outputting a preliminary positive region, performing SAPD algorithm optimization according to the preliminary positive region to obtain a positive region, performing parameter extraction on the positive region to obtain the pixel number of an MAFG positive region, the pixel number of an HMOX1 positive region and the area of a single pixel, and based on the pixel number of the MAFG positive region, the pixel number of the HMOX1 positive region and the single pixel area, carrying out calculation to obtain tumor protein quantitative analysis parameters. The method can realize quantitative evaluation of oncoprotein.

The invention provides a puncture sample detection platform based on a tumor protein targeting probe. According to the puncture sample detection platform, IR-780 is used for marking tumor specific protein in a puncture sample; the improved three-dimensional gel electrophoresis device is used for separating proteins in tissues; the gel processing platform is used for processing and analyzing the separation gel medium; and the automatic diagnosis platform is used for automatically judging benign and malignant conditions of the puncture sample according to the intensity and coherence of the fluorescence signal and circling the contour of the malignant sample. Compared with clinical pathological examination, the method has the advantages that benign and malignant puncture samples are judged by evaluating the protein content of various tumor receptors, and the problem of diagnosis difficulty caused by limited histological information is well solved. Meanwhile, the dependence on visual diagnosis of pathological analysis of the frozen section and experience of pathologists is reduced, and the accuracy and efficiency of pathological tissue diagnosis are effectively improved. The automatic diagnosis platform can eliminate a large number of benign samples and can reduce repeated work of pathologists.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

Provided herein are methods for producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

The invention relates to the technical field of pathological diagnosis, in particular to a tumor grading detection system based on holoproteome cysteine reactivity analysis, which comprises an in-situ labeling module, an in-situ detection module and an in-situ detection module, the histological separation module is used for carrying out molecular weight layering separation on the labeled tumor protein and counting the fluorescence signal intensity of each layer; the processing and analysis module is used for constructing a proteome-level cysteine reactivity map with position resolution capability; the tumor grading module is used for carrying out normalization processing on the average fluorescence intensity of each layer and the highest signal layer to obtain normalized intensity T, drawing a component specificity risk curve by taking the number of layers as a horizontal coordinate, and recording the area under the curve as the normalized intensity T as TSI; the TSI is in positive correlation with the tumor malignancy degree and serves as the basis of tumor grading. The method can accurately diagnose a tumor positive area, and the specificity and the sensitivity are both 100%.

The invention discloses application of Wilms oncoprotein-1 (WTAP) related protein in rheumatoid arthritis, finds that the specific expression level of WTAP in RA is increased for the first time, and finds that the WTAP regulates the polarization reaction of macrophages in a targeted manner so as to regulate the inflammation level of RA through overexpression and interference of WTAP and detection and verification of a WB method and an RT-qPCR method. Therefore, the preparation for detecting Wilms oncoprotein-1 (WTAP) related protein can be used for preparing a rheumatoid arthritis diagnosis preparation. The invention verifies the correlation between WTAP and RA inflammatory response and the regulation function on inflammation, and the WTAP has higher detection sensitivity and specificity on RA disease activity, and can be used for evaluating RA disease progression and relieving RA inflammatory response.

This invention discloses a polypeptide that specifically binds to the RNA-binding domain of the PRMT5 protein and its applications, belonging to the field of biomedical technology. The polypeptide specifically binds to the RNA-binding domain of the PRMT5 protein, and its amino acid sequence includes sequence A or sequence B. Sequence A is: LTNKKGFPVLSK; sequence B is: PGMFSWFPILFP. This polypeptide can precisely interfere with PRMT5-RNA interaction without affecting PRMT5 protein abundance, thereby specifically disrupting a key pathway for maintaining tumor protein translation. This polypeptide therapeutic agent has been shown to effectively inhibit tumor growth in preclinical models, validating the therapeutic feasibility of the "PRMT5-RBD targeting" strategy and providing a novel potential treatment option for patients (including those insensitive to or resistant to existing methylation inhibitors).

The application belongs to the field of electrochemistry, and relates to tumor protein P53 gene detection, in particular to a label-free double-color test strip, a kit and a preparation method thereof for tumor protein P53 gene detection. The application belongs to a novel LFA method, which combines DNA hybridization chain reaction with the electrostatic adsorption principle of test line / control line, selects common and cost-effective bovine serum albumin as the test line, utilizes the difference in the adsorption capacity of BSA to double-stranded DNA and nano-gold, and the different flow rates of different molecules on the NC membrane to complete the detection of p53 at different concentrations. The test line is constructed by positively charged PDDA to ensure the effectiveness of the LFA. Meanwhile, the detection principle of a liquid colorimetric sensor is combined, and the double-color development greatly reduces the detection limit of the test strip. The sensor is label-free throughout, and has high analytical performance in terms of sensitivity, selectivity and practicability. The p53 gene is detected on the lateral flow test strip for the first time.

The present disclosure, in some aspects, provides Co-stimulatory Conditional Bispecific Redirected Activation constructs, or “co-stim COBRA,” that are administered in an active prodrug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well and immune cells (e.g., one or more types of immune cells), thus recruiting immune cells to tumor, resulting in treatment.

The invention relates to an autologous cancer vaccine and its preparation method. The autologous vaccine according to the present invention is based on hydroxyapatite and / or tricalcium phosphate particles onto which tumor proteins are adsorbed, these tumor proteins being enriched in HSP110.

Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.

Methods of treating a cancer comprising a mutation in tumor protein p53 (TP53) or DNA mismatch repair protein Mlhl (MLH1) comprising: determining the cancer comprises the mutation and administering an agent that decreases abundance or function of a protein synthetically lethal with TP53 or MLH1 are provided. Agents that decrease abundance or function of a protein synthetical lethal with TP53 or MLH1 for use in treating a cancer comprising a mutation in TP53 or MLH1 are also provided.

A PET / SPECT probe includes the following formula:P-L-Cwherein P is a EDB-FN targeting peptide, C is a PET / SPECT contrast agent; and L is an optional linker that covalently links the peptide to the contrast agent.

In certain aspects, provided herein are therapeutic compositions comprising an mRNA formulated in a lipid nanoparticle (LNP), wherein the mRNA comprises an open reading frame encoding p53 polypeptide, and methods of using the same.

A novel binding molecule or a fragment thereof and uses thereof are disclosed. The novel binding molecule or a fragment thereof specifically bind to an extracellular translationally controlled tumor protein (TCTP). The binding molecule and the fragment thereof can be used to diagnose, treat, or prevent cancer. The binding molecule and the fragment thereof can be used to alleviate or prevent immune suppression in a tumor immune microenvironment. The binding molecule and the fragment thereof can be used to diagnose, treat, or prevent cancer in a patient who has no response, has a limited response, or is likely to have such a response to treatment using a cancer immunotherapeutic agent.

The present invention aims to identify regulatory factors of the cancer immune microenvironment and to provide methods for the therapeutic use of these regulatory factors. [Solution] Specifically, the present invention is an inhibitor of the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor immune microenvironment (TIME), comprising as an active ingredient a substance that suppresses or inhibits the function of immunomodulatory factors released from tumor dead cells. More specifically, the inhibitor comprises, for example, a substance that suppresses or inhibits the function of TCTP (translationally controlled tumor protein).

To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

The present invention relates to a conditionally bispecific redirected activation construct or COBRA administered in the form of an active prodrug. Upon exposure to a tumor protease, the constructs are cleaved and activated such that they are able to bind both tumor target antigens (TTAs) and CD3, thereby recruiting CD3-expressing T cells to the tumor for treatment. In some embodiments, the tumor target antigen is B7H3.

The application belongs to the field of anti-solid tumor drugs, and particularly relates to application of GSK-F1 in preparation of a drug for reducing NSUN2 protein stability, solid tumor targeted treatment and / or radiotherapy sensitization. Researches of the application show that GSK-F1 has the effect of inhibiting NSUN2 protein stability, and can realize targeted treatment of solid tumors and radiotherapy sensitization based on inhibition of NSUN2 tumor protein stability.

The invention relates to an autologous cancer vaccine and to the method for preparing same. The autologous vaccine according to the present invention is based on hydroxyapatite and / or tricalcium phosphate particles on which tumor proteins are adsorbed, these tumor proteins being enriched in HSP110.

The present invention relates to a novel binding molecule or a fragment thereof that specifically binds to extracellular TCTP (translationally controlled tumor protein). The present invention also relates to a binding molecule or a fragment thereof according to the present invention, and uses thereof. The binding molecule and a fragment thereof according to the present invention can be used to diagnose, treat, or prevent cancer. The binding molecule and a fragment thereof according to the present invention can be used to alleviate or prevent immunosuppression in the tumor immune microenvironment. The binding molecule and a fragment thereof according to the present invention can be used to diagnose, treat, or prevent cancer in patients who have failed to respond or have only responded to treatment using immunoanticancer drugs, or who are likely to do so.

To provide many different protein compositions for the treatment of cancer.SOLUTION: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.SELECTED DRAWING: None

A system and method for preparing a cancer vaccine (and optionally purifying blood) comprises a hemofiltration system controlled by a control unit for filtering exogenous plasma to isolate tumor cells, tumor stem cells, and tumor degradation products. The hemofiltration system filter may include multiple layers with openings of different sizes to hold substances of different sizes (from among tumor cells, tumor stem cells, and tumor degradation products of different sizes). The apparatus directs electromagnetic radiation to the isolated tumor cells, tumor stem cells, and / or tumor degradation products, which can cause a coagulated outer layer by degrading the outer surface of the isolated tumor cells, isolated tumor stem cells, and / or isolated tumor degradation products (e.g., tumor proteins such as DNA and / or tumor exosomes). The electromagnetic radiation may have a UV wavelength. A conical coil improves flow uniformity. Tumor exosomes can be centrifuged.

A system and process for producing a cancer vaccine (and optionally for purifying the blood) includes a blood filtration system controlled by a processing unit to filter exogenous blood plasma and isolate tumor cells, tumor stem cells, and tumor degradation products. The filter of the blood filtration system can comprise multiple layers with differently sized openings to retain materials of varying sizes (from tumor cells of different sizes, tumor stem cells, and tumor degradation products). A device directs electromagnetic radiation at the isolated tumor cells, tumor stem cells, and / or tumor degradation products. The electromagnetic radiation can cause the isolated tumor cells, isolated tumor stem cells, and / or isolated tumor degradation products (e.g., tumor proteins such as DNA and / or tumor exosomes) to have a coagulated outer layer, for example, by degrading the outer surface.The electromagnetic radiation can have a UV wavelength. A conical coil improves the uniformity of the flow rate. Tumor exosomes can be centrifuged.

The invention belongs to the field of anti-solid tumor drugs, and particularly relates to application of GSK-F1 in preparation of drugs for reducing the stability of NSUN2 protein, targeted therapy of solid tumors and / or radiotherapy sensitization. The research shows that the GSK-F1 has the effect of inhibiting the stability of the NSUN2 protein, and can realize targeted therapy and radiotherapy sensitization on solid tumors on the basis of inhibiting the stability of the NSUN2 tumor protein.

The present invention discloses a target protein degrader based on etacrynic acid and its application, which relates to the technical field of drug development. It includes a target protein degrader based on etacrynic acid, which has the structure shown in the following formula (I): R1LR2 Formula (I); wherein: R1 is etacrynic acid EA; R2 is the ligand JQ1 of bromodomain protein 4; L is a linker chain, and the R1 and R2 are connected by L; for the target protein degrader based on etacrynic acid and its application, the target protein BRD4 is degraded by recruiting the E3 ubiquitin ligase HECTD1 through etacrynic acid, and this process is achieved through the ubiquitin-proteasome, avoiding drug resistance caused by target mutations. It not only provides a new choice for the recruiting molecule of the target protein degrader, but also provides a new E3 ubiquitin ligase, providing a new construction idea for the degrader of difficult-to-target tumor proteins, and having good application in the preparation of anticancer drugs.